Preclinical development of a T cell product tunable by soluble factors for melanoma and glioblastoma patients refractory to prior intratumoral immunotherapy.

Medicine & Life Sciences

1. Immunotherapy 100%
2. Melanoma 77%
3. Glioblastoma 71%
4. T-Lymphocytes 63%
5. Neoplasms 19%
6. Adoptive Immunotherapy 13%
7. Neoplasm Metastasis 12%
8. Blocking Antibodies 12%
9. Myeloid Cells 10%
10. Cell- and Tissue-Based Therapy 9%
11. Dendritic Cells 9%
12. Clinical Trials 6%
13. Phenotype 6%